SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Kayak Therapeutics Announces IND Clearance for KT-300

The company said KT-300 is an oral small-molecule TRIM7 inhibitor designed to target RAS-driven cancers.

Related stories